These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18849646)

  • 1. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells.
    Scaglione F; Lucini V; Pannacci M; Caronno A; Leone C
    Pharmacology; 2008; 82(4):270-5. PubMed ID: 18849646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the potency of 10 different brands of Serenoa repens extracts.
    Scaglione F; Lucini V; Pannacci M; Dugnani S; Leone C
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):569-74. PubMed ID: 22774395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
    Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
    Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract.
    Habib FK; Wyllie MG
    Prostate Cancer Prostatic Dis; 2004; 7(3):195-200. PubMed ID: 15289814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
    Bayne CW; Donnelly F; Ross M; Habib FK
    Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
    Habib FK; Ross M; Ho CK; Lyons V; Chapman K
    Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines.
    Hostanska K; Suter A; Melzer J; Saller R
    Anticancer Res; 2007; 27(2):873-81. PubMed ID: 17465214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenoa repens and benign prostatic hyperplasia: no more effective than placebo.
    Prescrire Int; 2010 Aug; 19(108):181-2. PubMed ID: 20941857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia.
    Sinescu I; Geavlete P; Multescu R; Gangu C; Miclea F; Coman I; Ioiart I; Ambert V; Constantin T; Petrut B; Feciche B
    Urol Int; 2011; 86(3):284-9. PubMed ID: 21304222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation.
    Iglesias-Gato D; Carsten T; Vesterlund M; Pousette A; Schoop R; Norstedt G
    Phytother Res; 2012 Feb; 26(2):259-64. PubMed ID: 21656602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexanic Extract of Serenoa repens (Permixon
    Blair HA
    Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
    Amdii RE; Al' Shukri AS
    Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of permixon on human prostate cell growth: lack of apoptotic action.
    Hill B; Kyprianou N
    Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
    Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
    BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
    Plosker GL; Brogden RN
    Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serenoa repens in benign prostatic hyperplasia].
    Log T
    Tidsskr Nor Laegeforen; 2008 May; 128(11):1293-4. PubMed ID: 18511974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation.
    Giulianelli R; Pecoraro S; Sepe G; Leonardi R; Gentile BC; Albanesi L; Brunori S; Mavilla L; Pisanti F; Giannella R; Morello P; Tuzzolo D; Coscione M; Galasso F; D'Angelo T; Ferravante P; Morelli E; Miragliuolo A;
    Arch Ital Urol Androl; 2012 Jun; 84(2):94-8. PubMed ID: 22908779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth.
    Altavilla D; Bitto A; Polito F; Irrera N; Marini H; Arena S; Favilla V; Squadrito F; Morgia G; Minutoli L
    J Urol; 2011 Oct; 186(4):1524-9. PubMed ID: 21855911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study.
    Morgia G; Cimino S; Favilla V; Russo GI; Squadrito F; Mucciardi G; Masieri L; Minutoli L; Grosso G; Castelli T
    Int Braz J Urol; 2013; 39(2):214-21. PubMed ID: 23683667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.